NCT01216280 - Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions

Ulcerative Colitis

Interventions

DRUG

placebo capsule

2 x 10 mg placebo capsules administered orally with water, b.i.d.

DRUG

10 mg Natura-alpha capsule and 10 mg placebo capsule

10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.

DRUG

2 x 10 mg Natura-alpha capsules

2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.

Trial Locations (10)

Long Island Clinical Research Associates, LLP, Great Neck

Premier Medical Group of the Hudson Valley, Poughkeepsie

Chevy Chase Clinical Research, Chevy Chase

Nashville Medical Research Institute, Nashville

Consultants for Clinical Research, Fairfield

Consultants for Clinical Research, Cincinnati

Wisconsin Center for Advanced Research, LLC, Milwaukee

Kansas City Gastroenterology and Hepatology, Kansas City

Advanced Clinical Research Institute, Anaheim

AGA Medical Research Associates, LLC, Egg Harbor